OtherClinical Investigations
Whole-Body 18F-FDG PET Identifies High-Risk Myeloma
Brian G.M. Durie, Alan D. Waxman, Allesandro D’Agnolo and Cindy M. Williams
Journal of Nuclear Medicine November 2002, 43 (11) 1457-1463;
Brian G.M. Durie
Alan D. Waxman
Allesandro D’Agnolo
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Whole-Body 18F-FDG PET Identifies High-Risk Myeloma
Brian G.M. Durie, Alan D. Waxman, Allesandro D’Agnolo, Cindy M. Williams
Journal of Nuclear Medicine Nov 2002, 43 (11) 1457-1463;
Related Articles
- No related articles found.
Cited By...
- Multiple myeloma with central nervous system relapse
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- Multiple Myeloma, Version 2.2016
- In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy
- In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
- Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma
- 11C-Acetate PET/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with 18F-FDG PET/CT
- The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma
- Imaging in myeloma
- Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy
- Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- Multiple Myeloma
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
- Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
- Multiple Myeloma
- Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-Aminoadenosine
- A new pet for myeloma
- NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
- FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma
- Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters
- 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma
- Multiple Myeloma Presenting With [18F]Fluorodeoxyglucose Avid Liver Lesions Diagnosed on Positron Emission Tomography Scan
- A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma
- Artifactual Spinal Metastases Imaged by PET/CT: A Case Report
- Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
- Plasma Cell Problems: CASE 3. Plasmacytoma Mimicking a Paraganglioma of the Skull Base: Diagnostic Value of Somatostatin Receptor Scintigraphy
- Side Effects and Good Effects from New Chemotherapeutic Agents: CASE 3. Bortezomib in Primary Refractory Plasmacytoma
- Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials
- Unusual Presentations of Hematologic Malignancies: CASE 1. Solitary Bone Plasmacytoma: Role of Magnetic Resonance Imaging and Positron Emission Tomography
- Treatment of multiple myeloma